Secondary Causes of Hypertension

Common Secondary Causes

• The American Heart Association suggests that renal parenchymal disease presents with history of urinary tract infections, obstruction, hematuria, urinary frequency, nocturia, or family history of polycystic kidney disease 1, 2
• The American College of Cardiology recommends that renovascular disease is suspected in cases with abrupt onset or worsening hypertension, flash pulmonary edema, or early-onset hypertension, especially fibromuscular dysplasia in women 1, 3
• The European Society of Cardiology states that primary aldosteronism affects 8-20% of resistant hypertension cases and presents with hypokalemia, muscle cramps/weakness, or family history of early-onset hypertension 1, 4
• The American Heart Association notes that pheochromocytoma is uncommon but dangerous, presenting with episodic symptoms, labile hypertension 5, 4
• The European Heart Journal recommends that obstructive sleep apnea is present in 25-50% of resistant hypertension cases and is associated with snoring, daytime sleepiness, obesity, and non-dipping nocturnal BP pattern 1, 2

Clinical Clues Suggesting Secondary Hypertension

• The American College of Cardiology suggests that age of onset <30 years, severe or resistant hypertension, abrupt onset or sudden deterioration of previously controlled hypertension, and hypertensive urgency or emergency are clinical clues suggesting secondary hypertension 5, 2, 6
• The Journal of the American College of Cardiology recommends that target organ damage disproportionate to duration or severity of hypertension and presence of clinical features specific to secondary causes are also clues 6, 1, 2

Diagnostic Approach

• The American Heart Association recommends basic screening for all suspected cases, including thorough history and physical examination, basic blood biochemistry, urinalysis, fasting blood glucose or HbA1c, thyroid function tests, and ECG 2, 7, 6
• The European Heart Journal suggests targeted screening based on clinical suspicion, including plasma aldosterone-to-renin ratio for primary aldosteronism, renal ultrasound for renovascular disease, and polysomnography for obstructive sleep apnea 1, 2, 8

Management Principles

• The American College of Cardiology recommends treating the underlying cause, including medical therapy for atherosclerotic renovascular disease, adrenalectomy for unilateral primary aldosteronism, and CPAP therapy for moderate-severe obstructive sleep apnea 7, 8
• The European Society of Cardiology suggests optimizing antihypertensive therapy while addressing the underlying cause, using appropriate agents based on the specific secondary cause, and considering adding spironolactone as fourth-line agent for resistant hypertension 2, 9

Lifestyle Modifications

• The American Heart Association recommends sodium restriction, limiting alcohol consumption, and weight loss for obese patients, especially those with sleep apnea 5, 4, 8

Treatment Approach for Secondary Hypertension

Identification and Diagnosis

• The American Heart Association recommends screening for secondary hypertension in patients with early-onset hypertension, resistant hypertension, sudden deterioration in blood pressure control, hypertensive urgency/emergency, or strong clinical clues suggesting secondary causes 10
• Basic screening should include thorough history, physical examination, basic blood biochemistry, and urinalysis 10
• Further investigations should be based on clinical suspicion from initial evaluation 10, 11
• Consider referral to specialist centers with expertise in diagnosing and managing secondary hypertension 10, 12

Treatment Based on Specific Causes

• For primary aldosteronism, the European Society of Cardiology recommends surgical removal of the adrenal gland for unilateral cases 12
• For bilateral primary aldosteronism, medical treatment with mineralocorticoid receptor antagonists (MRAs) is recommended 12
• The American Journal of Kidney Diseases suggests using spironolactone (50-100 mg daily) as the most widely used MRA 12
• For atherosclerotic renal artery stenosis, medical therapy is recommended 11
• For fibromuscular dysplasia, percutaneous transluminal renal angioplasty without stenting is the treatment of choice 12, 13
• The European Heart Journal recommends addressing the underlying renal disease with specific treatments for renal parenchymal disease 13
• Monitor renal function carefully when using RAS blockers 12

Management of Resistant Hypertension

• The American Heart Association recommends optimizing current treatment regimen including lifestyle changes and diuretic-based treatment 10
• Use thiazide-like rather than thiazide diuretics, and consider loop diuretics for eGFR <30 ml/min/1.73m² 10
• Add spironolactone as fourth-line agent (if serum potassium <4.5 mmol/L and eGFR >45 ml/min/1.73m²) 10, 12
• Renal denervation may be considered for resistant hypertension uncontrolled despite a three-drug combination 12

Follow-up and Monitoring

• Regular monitoring of blood pressure, renal function, and electrolytes is essential 10
• Evaluate treatment response and adjust therapy as needed 10
• Consider lifelong treatment if hypertension persists despite addressing the underlying cause 14

Pitfalls and Caveats

• Secondary hypertension is often underrecognized, affecting 5-10% of hypertensive patients 10
• Delayed diagnosis can lead to vascular remodeling, affecting renal function and resulting in residual hypertension even after treating the underlying cause 12
• Combining two RAS blockers (ACE inhibitor and ARB) is not recommended 14
• Even after treating the underlying cause, some patients may require ongoing antihypertensive therapy 12

Initial Work-up for Secondary Hypertension

Clinical Evaluation

• The European Society of Cardiology recommends an initial work-up for suspected secondary hypertension that includes routine laboratory tests and a 12-lead ECG to screen for common causes and assess cardiovascular risk 15
• Resistant hypertension, defined as blood pressure greater than 140/90 mmHg despite optimal doses of at least three antihypertensive drugs including a diuretic, suggests secondary hypertension 16

Comprehensive History and Physical Examination

• A comprehensive history should focus on the duration and previous levels of high blood pressure, symptoms suggesting secondary causes, medication use, lifestyle factors, and family history of hypertension or endocrine disorders 17
• Physical examination should include features of Cushing syndrome, skin stigmata of neurofibromatosis, palpation for enlarged kidneys, auscultation for abdominal murmurs, and assessment of femoral pulses 18

Routine Laboratory Tests

• Routine laboratory tests should include fasting blood glucose and HbA1c, serum lipids, blood sodium and potassium, blood creatinine and eGFR, urinalysis and urinary albumin-to-creatinine ratio, thyroid-stimulating hormone, and a 12-lead ECG 15

Further Investigations

• For suspected primary aldosteronism, further investigations may include confirmatory testing with an intravenous saline suppression test, adrenal imaging with a CT scan, and adrenal vein sampling 16
• For suspected renovascular disease, further investigations may include renal ultrasound with Doppler and CT or MR renal angiography 15
• For suspected pheochromocytoma, further investigations may include 24-hour urinary catecholamines or metanephrines and abdominal/adrenal imaging 16
• For suspected obstructive sleep apnea, further investigations may include home sleep apnea testing or polysomnography 16

Common Pitfalls to Avoid

• The European Heart Journal warns against failing to consider medication-induced hypertension before extensive workup 17
• The American Heart Association suggests that expensive imaging studies should not be performed before completing basic laboratory screening 16
• Referral to specialized centers with appropriate expertise is recommended for complex cases 16

Secondary Hypertension Diagnosis and Management

Clinical Assessment and Diagnosis

• The American Heart Association recommends assessing for cardiovascular key findings, including radio-femoral delay, in patients with suspected secondary hypertension 19
• The American College of Cardiology suggests evaluating for endocrine/metabolic signs, such as fatty deposits and colored striae, in patients with suspected Cushing syndrome 19
• Patients with suspected primary aldosteronism should be evaluated for arrhythmias and other symptoms, according to the American Heart Association 19
• The American Academy of Sleep Medicine recommends assessing for obstructive sleep apnea in patients with resistant hypertension and symptoms such as snoring and daytime sleepiness 19

Laboratory Screening and Testing

• The American Heart Association recommends performing basic laboratory screening, including serum sodium and potassium, serum creatinine and eGFR, and urinalysis, in all suspected cases of secondary hypertension 19, 20
• The Endocrine Society suggests testing for primary aldosteronism with plasma aldosterone-to-renin ratio, followed by confirmatory testing, in patients with resistant hypertension and spontaneous or diuretic-induced hypokalemia 19, 20
• The American College of Cardiology recommends testing for renovascular disease with renal ultrasound with Duplex Doppler, followed by CT or MR renal angiography, in patients with abrupt onset or worsening hypertension 19, 20

Imaging and Specialized Testing

• The American Heart Association recommends echocardiography to assess for left ventricular hypertrophy, aortic coarctation, and systolic/diastolic dysfunction in patients with suspected secondary hypertension 19, 20
• The American Academy of Ophthalmology suggests fundoscopy to evaluate for retinal changes, hemorrhages, and papilledema in patients with suspected secondary hypertension 19, 20

Diagnostic Approach to Secondary Hypertension

Initial Evaluation and Screening

• The European Society of Cardiology (ESC) 2024 guidelines recommend measuring renin and aldosterone in all adults with confirmed hypertension (Class IIa), representing a significant change from the traditional approach 21
• Patients with onset of hypertension before the age of 30 (or 40 according to ESC 2024) require comprehensive screening for primary causes of secondary hypertension 21
• Severe or resistant hypertension (blood pressure >140/90 mmHg with ≥3 antihypertensive medications, including a diuretic) warrants further investigation 22
• Sudden onset or sudden deterioration of previously controlled hypertension requires thorough evaluation 22

Targeted Investigations Based on Clinical Suspicion

• For primary aldosteronism (8-20% of resistant hypertension):
• For renovascular disease (5-34% in selected populations):

Management After Diagnosis

• For primary aldosteronism:
• For resistant hypertension (after excluding secondary causes):

Initial Laboratory Tests for Hypertension with Acanthosis Nigricans

Clinical Reasoning and Recommendations

• The American Heart Association recommends that laboratory examination of patients with resistant hypertension should include a paired morning plasma aldosterone and plasma renin activity (PRA) to screen for primary aldosteronism 23, 24, 25
• The aldosterone-to-renin ratio (ARR) has a high negative predictive value for screening primary aldosteronism, making it an effective initial test 23, 26
• A high ratio (>20) when serum aldosterone is elevated and PRA is low is suggestive of primary aldosteronism 23, 25

Diagnostic Criteria and Pitfalls

• Plasma catecholamines and urinary metanephrines are appropriate for screening pheochromocytoma, but this condition presents with episodic symptoms and labile hypertension—not the clinical picture described here 23, 24
• The American Heart Association states that measurement of plasma or urinary metanephrines is indicated only when pheochromocytoma is specifically suspected based on clinical features 23, 25
• Interpretation of the aldosterone-to-renin ratio can be affected by certain antihypertensive medications: mineralocorticoid receptor antagonists raise aldosterone levels, while beta-blockers and direct renin inhibitors lower renin levels 23, 26

Comprehensive Initial Workup

• Basic metabolic profile (serum electrolytes, glucose, blood urea nitrogen, and creatinine) should be included in the initial evaluation 23, 26
• Hypokalemia, if present, would further support the diagnosis of primary aldosteronism 23
• Urinalysis and urinary albumin-to-creatinine ratio to assess for kidney damage 23

Secondary Hypertension Diagnosis and Management

Initial Screening and Diagnosis

• The European Society of Cardiology recommends assessing renal function with serum creatinine and eGFR, and performing urinalysis and urinary albumin-to-creatinine ratio to detect proteinuria and kidney damage in all suspected cases of secondary hypertension 27
• The European Society of Cardiology also recommends a 12-lead ECG for all patients with hypertension, as part of the initial screening 27
• Echocardiography is recommended for patients with ECG abnormalities or signs/symptoms of cardiac disease, according to the European Heart Journal 27
• Fundoscopy is recommended if BP >180/110 mmHg to evaluate for hypertensive emergency and malignant hypertension, as per the European Heart Journal 27

Targeted Investigations and Management

• The European Society of Cardiology guidelines recommend measuring renin and aldosterone in all adults with confirmed hypertension, with a Class IIa recommendation 27

Secondary Hypertension Diagnosis and Management

Initial Evaluation and Screening

• The American Heart Association recommends assessing for left ventricular hypertrophy using a 12-lead ECG in patients with suspected secondary hypertension 28
• Urinary albumin-to-creatinine ratio is a useful screening test for renal disease in patients with hypertension, with abnormal results indicating potential renal parenchymal disease 28
• Renal Duplex Doppler ultrasound is a recommended initial imaging test for renovascular disease in patients with suspected secondary hypertension 28
• CT or MRI renal angiography can be used as confirmatory tests for renovascular disease in patients with suspected secondary hypertension 28
• Renal ultrasound is a useful imaging test for assessing kidney size, echogenicity, and structural abnormalities in patients with suspected renal parenchymal disease 28

Guidelines for Screening, Diagnosis, and Referral in Secondary Hypertension

Epidemiology

Clinical Red‑Flag Indicators

Primary Aldosteronism

Renovascular Disease

Pheochromocytoma

Obstructive Sleep Apnea (OSA)

Cushing Syndrome

Initial Laboratory Screening (Class IIa recommendation)

Physical Examination Findings Suggestive of Specific Causes

Confirmatory Testing Based on Clinical Suspicion

Primary Aldosteronism

Renovascular Disease

Pheochromocytoma

Obstructive Sleep Apnea

Cushing Syndrome

Medication Effects on ARR Testing

Referral Recommendations

Evaluation and Management of Endocrine‑Related Hypertension

1. Screening and Red‑Flag Identification

• Patients with resistant hypertension (BP > 140/90 mm Hg on ≥ 3 antihypertensives including a diuretic), early‑onset hypertension (< 30 years), or sudden deterioration of previously controlled BP should be screened for endocrine causes, with primary aldosteronism prioritized as the most common treatable etiology. 32, 33
• Resistant hypertension despite optimal triple therapy that includes a diuretic is a red flag for secondary endocrine hypertension. 34, 35
• Abrupt onset or rapid worsening of previously controlled BP constitutes a red flag for an endocrine etiology. 32, 33

2. Symptom‑Based Clinical Assessment

Primary Aldosteronism

• Accounts for 8–20 % of resistant hypertension cases. 32, 33
• Presents with muscle weakness, tetany, cramps, or arrhythmias secondary to hypokalemia. 32, 33
• Spontaneous or diuretic‑induced hypokalemia supports the diagnosis. 34, 35

Pheochromocytoma

• The classic triad of episodic sweating, palpitations, and frequent headaches suggests pheochromocytoma. 32, 33

Cushing Syndrome

• Typical features include central obesity with thin extremities, wide (> 1 cm) purple striae, and easy bruising. 34, 35
• Additional signs: proximal muscle weakness, moon‑shaped face, “buffalo hump,” and fatty deposits. 32, 33, 34

Thyroid Disease

• Hypothyroidism: dry skin, cold intolerance, constipation, weight gain, delayed ankle reflexes. 34, 35
• Hyperthyroidism: warm moist skin, heat intolerance, tremor, weight loss, tachycardia. 34, 35

3. Physical‑Examination Findings

• Radio‑femoral delay suggests coarctation of the aorta. 32, 33
• Abdominal systolic‑diastolic bruits indicate renovascular disease. 36
• Neck circumference > 40 cm raises suspicion for obstructive sleep apnea. 32, 33
• Enlarged thyroid gland may point to thyroid dysfunction. 32, 33
• Colored striae and fatty deposits are characteristic of Cushing syndrome. 32, 33, 34
• Enlarged hands/feet (acral enlargement) suggest acromegaly. 34, 35

4. Baseline Laboratory Screening (All Suspected Cases)

• Serum sodium and potassium; hypokalemia supports primary aldosteronism. 32, 33
• Serum creatinine and estimated glomerular filtration rate (eGFR). 32, 33
• Urinalysis with albumin‑to‑creatinine ratio. 32, 33
• Fasting glucose or HbA1c. 32, 33
• 12‑lead ECG to assess for left ventricular hypertrophy. 32, 33

5. Confirmatory Testing Based on Screening Results

Primary Aldosteronism

• Intravenous saline suppression test or oral sodium‑loading test for biochemical confirmation. 32, 33
• Adrenal vein sampling when surgical intervention is contemplated to differentiate unilateral from bilateral disease. 32, 33

Pheochromocytoma

• 24‑hour urinary metanephrines/normetanephrines or plasma free metanephrines for biochemical diagnosis. 32, 33
• Abdominal/adrenal CT or MRI after biochemical confirmation. 34, 35

Cushing Syndrome

• Late‑night salivary cortisol or 24‑hour urinary free cortisol for screening. 32, 33

Renovascular Disease

• CT or MR renal angiography for definitive diagnosis when indicated. 32, 33

6. Management Strategies

Primary Aldosteronism

• Unilateral adrenalectomy for unilateral aldosterone‑producing adenoma (curative).
• Spironolactone 50–100 mg daily for bilateral adrenal hyperplasia or non‑surgical candidates.
• Eplerenone is an alternative mineralocorticoid‑receptor antagonist. 34, 35

Pheochromocytoma

• Pre‑operative alpha‑blockade followed by beta‑blockade before surgical resection.
• Laparoscopic adrenalectomy for adrenal tumors; open approach for paragangliomas.

Cushing Syndrome

• Surgical removal of the underlying cause when feasible. 36
• Adequate diuretic therapy is essential for BP control due to mineralocorticoid‑receptor activation. 36

Renovascular Disease

• Percutaneous transluminal renal angioplasty without stenting for fibromuscular dysplasia. 36

7. Optimizing Antihypertensive Therapy After Excluding Secondary Causes

• Ensure adherence to a regimen of a renin‑angiotensin system blocker, a calcium‑channel blocker, and a thiazide‑like diuretic (chlorthalidone or indapamide) at maximal tolerated doses. 34, 35
• Add spironolactone as a fourth‑line agent when serum potassium < 4.5 mmol/L and eGFR > 45 mL/min/1.73 m². 34, 35
• Substitute loop diuretics for thiazides when eGFR < 30 mL/min/1.73 m². 34, 35

8. Lifestyle Modifications

• Sodium intake restriction to < 2400 mg/day. 34, 35

9. Referral Recommendations

• Refer to a hypertension specialist or endocrinologist when confirmatory testing is required, complex procedures (e.g., adrenal vein sampling) are contemplated, surgical intervention is being considered, or BP remains uncontrolled despite optimal medical therapy. 34, 35

Investigation and Management of Secondary Hypertension

Indications for Investigating Secondary Causes

• Screen for secondary hypertension when blood pressure stays > 140/90 mmHg despite optimal doses of three antihypertensive agents (including a diuretic), when hypertension begins < 30 years or > 50 years of age, when previously controlled pressure suddenly worsens, or when severe hypertension is accompanied by grade III–IV retinopathy. 37
• Target‑organ damage that is disproportionate to the duration or severity of hypertension should trigger evaluation for a secondary cause. 38

Baseline Laboratory Screening

• Spontaneous or diuretic‑induced hypokalemia (low serum potassium) is a strong clue for primary aldosteronism in hypertensive patients. 37
• Measurement of thyroid‑stimulating hormone (TSH), with free T4/T3 as indicated, is recommended as part of the initial work‑up for secondary hypertension. 37

Clinical Clues Guiding Targeted Testing

• Features suggestive of Cushing syndrome—central obesity, wide purple striae, easy bruising, proximal muscle weakness, moon facies, buffalo hump—warrant specific hormonal screening in hypertensive individuals. 37
• Signs of thyroid disease:
  
  • Hypothyroidism – dry skin, cold intolerance, weight gain, delayed reflexes, periorbital puffiness, coarse skin.
  • Hyperthyroidism – heat intolerance, tremor, weight loss, insomnia, tachycardia.
• In patients < 30 years, a systolic blood‑pressure difference > 10 mmHg between arm and thigh or a palpable radio‑femoral delay suggests coarctation of the aorta; confirmatory imaging with CT angiography or MRI is indicated. [39][38]39

Physical Examination Findings by Etiology

• Radio‑femoral delay → coarctation of the aorta.
• Abdominal systolic‑diastolic bruits → renovascular disease.
• Jugular venous distension + peripheral edema → flash pulmonary edema from renovascular disease.
• Colored striae + fatty deposits → Cushing syndrome.
• Enlarged thyroid gland → thyroid dysfunction.
• Palpable enlarged kidneys → renal parenchymal disease (e.g., polycystic kidney disease).

Common Pitfalls to Avoid

• Medication non‑adherence accounts for a large share of apparent resistant hypertension; clinicians should ask explicitly about missed doses, side‑effect concerns, and cost barriers. [40][39]
• Several drugs (NSAIDs, decongestants, stimulants, oral contraceptives, cyclosporine, erythropoietin, licorice, ephedra) can induce hypertension and must be reviewed in resistant cases. 40
• Ambulatory or home blood‑pressure monitoring should be used to exclude white‑coat hypertension, which occurs in 20‑30 % of patients with apparent resistant hypertension. [41][40]38

Criteria for Specialist Referral

• Positive screening tests that require confirmatory evaluation (e.g., aldosterone‑renin ratio, metanephrines).
• Need for complex procedures such as adrenal vein sampling.
• Consideration of surgical treatment (e.g., unilateral adrenalectomy for primary aldosteronism).
• Persistent uncontrolled blood pressure after ≥ 6 months of optimal medical therapy. [42][43]42

Diagnostic Evaluation and Screening for Secondary Hypertension in Young Adults

Baseline Laboratory Assessment

• The European Society of Cardiology (ESC) guidelines recommend measuring serum creatinine and estimated glomerular filtration rate (eGFR) in all young hypertensive patients to evaluate kidney function and detect chronic kidney disease. [44][45]
• Serum electrolytes (sodium and potassium) should be obtained because spontaneous or diuretic‑induced hypokalemia strongly suggests primary aldosteronism. [44][45]
• Urine albumin‑to‑creatinine ratio (rather than dipstick alone) is advised to identify early renal damage and to stratify cardiovascular risk. [44][45]
• Fasting blood glucose or HbA1c testing is required to uncover diabetes mellitus, a condition that markedly raises cardiovascular risk. 45
• A fasting lipid profile (total cholesterol, LDL‑C, HDL‑C, triglycerides) is essential for cardiovascular risk stratification. 45
• Thyroid‑stimulating hormone (TSH) measurement screens for hypo‑ or hyper‑thyroidism, both of which are potentially reversible causes of hypertension. 45
• A complete blood count (hemoglobin/hematocrit) helps detect anemia or other hematologic abnormalities that may contribute to elevated blood pressure. 45
• A 12‑lead electrocardiogram is recommended to identify left ventricular hypertrophy, arrhythmias (including atrial fibrillation), and ischemic heart disease. [44][45]

Electrocardiographic and Imaging Evaluation

• Echocardiography should be performed when the ECG shows abnormalities, when cardiac symptoms are present, or (if resources allow) in all newly diagnosed hypertensive patients because it detects left ventricular hypertrophy and diastolic dysfunction that predict cardiovascular events even in young adults. 44
• Renal ultrasound with Doppler is indicated when renovascular disease is suspected based on clinical features, providing an anatomic assessment of renal arteries. [44][45]

Screening for Primary Aldosteronism

• The 2024 ESC hypertension guideline (Class IIa recommendation) advises measuring the plasma aldosterone‑to‑renin ratio (ARR) in all adults with confirmed hypertension, representing a paradigm shift from selective screening. 44
• Primary aldosteronism is responsible for approximately 8–20 % of resistant hypertension, underscoring the importance of routine ARR testing. 44

Physical‑Examination Indicators of Secondary Causes

• Radio‑femoral delay on pulse examination suggests coarctation of the aorta. 45
• Abdominal bruits on auscultation indicate possible renovascular disease. 45
• A neck circumference > 40 cm is a clinical clue for obstructive sleep apnea, a reversible contributor to hypertension. 45

Summary Table of Key Recommendations

All bullet points are derived from cited references 44 and 45, reflecting the ESC 2024 hypertension guideline and supporting peer‑reviewed literature.

Screening and Evaluation of Secondary Hypertension

Guideline Recommendations

• The European Society of Cardiology (ESC) 2024 guidelines (Class IIa) recommend universal measurement of the aldosterone‑renin ratio (ARR) in every adult with confirmed hypertension as a first‑line screening test for secondary causes. 46

High‑Risk Clinical Scenarios Requiring Immediate Work‑up

• Patients whose hypertension began before age 30 (or before age 40 according to ESC 2024) and who have no family history of hypertension should be promptly evaluated for secondary etiologies. 46
• Resistant hypertension—defined as blood pressure > 140/90 mmHg despite optimal doses of ≥ 3 antihypertensive agents, including a diuretic—warrants immediate secondary‑cause investigation. 46
• A sudden onset or rapid worsening of previously well‑controlled hypertension signals the need for urgent assessment for secondary mechanisms. 46
• Severe hypertension (systolic > 180 mmHg or diastolic > 110 mmHg) or hypertensive emergencies are high‑priority situations for secondary‑cause screening. 46
• Organ damage that appears disproportionate to the known duration or severity of hypertension should trigger immediate evaluation for an underlying secondary disorder. 46

Physical Examination Findings Suggestive of Specific Secondary Causes

• A radio‑femoral pulse delay is a key bedside sign of aortic coarctation. 47
• An abdominal systolic‑diastolic bruit raises suspicion for renovascular hypertension. 48
• Jugular venous distension together with peripheral edema may indicate flash pulmonary edema associated with renovascular disease. 47
• Palpable enlarged kidneys suggest polycystic kidney disease as a potential secondary cause. 48
• Neck circumference > 40 cm is a clinical cue for obstructive sleep apnea, a common contributor to resistant hypertension. 47

Laboratory Evaluation (Baseline Screening Before Advanced Imaging)

• Serum electrolytes (sodium, potassium); spontaneous or diuretic‑induced hypokalemia strongly points toward primary hyperaldosteronism. 46
• Serum creatinine and estimated glomerular filtration rate (eGFR) are required to assess renal function in all hypertensive patients. [46][47]
• Urine albumin‑creatinine ratio (UACR) should be measured rather than relying solely on dipstick testing. 47
• Fasting glucose or HbA1c should be obtained to identify concomitant diabetes mellitus. 47
• Thyroid‑stimulating hormone (TSH) measurement screens for thyroid disorders that can affect blood pressure. 47
• A fasting lipid profile is recommended for cardiovascular risk stratification. 47
• A 12‑lead electrocardiogram evaluates for left‑ventricular hypertrophy and atrial fibrillation. 47

Prevalence and Clinical Clues for Specific Secondary Hypertension Etiologies

• Primary hyperaldosteronism accounts for approximately 8–20 % of resistant hypertension cases. 47
  
  • Typical clues include muscle weakness, tetany, cramps, arrhythmias related to hypokalemia, and a family history of early‑onset hypertension. 47
• Renovascular hypertension is suspected when there is a sudden onset or worsening of hypertension, flash pulmonary edema, or a ≥ 50 % rise in serum creatinine within one week after initiating an ACE inhibitor or ARB. Initial imaging should be renal duplex Doppler ultrasound. 47
  
  • Confirmation is obtained with CT or MR renal angiography. 48
• Pheochromocytoma should be screened for in patients with episodic sweating, palpitations, headaches, and labile blood pressure using 24‑hour urinary metanephrines or plasma free metanephrines. 47
• Obstructive sleep apnea contributes to 25–50 % of resistant hypertension; clinical indicators include habitual snoring, observed apneas, daytime sleepiness, obesity, and a non‑dipping blood‑pressure pattern on ambulatory monitoring. 47
• Cushing syndrome, though rare, may present with central obesity, thin limbs, wide violaceous striae, easy bruising, proximal muscle weakness, moon face, and buffalo hump; screening utilizes late‑night salivary cortisol or 24‑hour urinary free cortisol. 47

Referral to Specialists

• Patients with a positive ARR, abnormal hormonal screens, or imaging findings that require confirmatory testing should be referred to an endocrinology or hypertension specialist. 46
• Complex cases that may need advanced procedures such as adrenal‑vein sampling are also indications for specialist referral. 46

Immediate Laboratory Work‑up for Patients Presenting with Periorbital Edema and Suspected Renal Involvement

• Obtain serum creatinine/eGFR, urine albumin‑creatinine ratio, serum electrolytes, and an aldosterone‑renin ratio as the first‑line laboratory panel. 47
• If eGFR is reduced or proteinuria is present, prioritize evaluation for renal parenchymal disease as the primary etiology. 48

Ultrasound Use in the Initial Evaluation of Suspected Arterial Hypertension

Routine Baseline Assessment

• In patients with newly diagnosed arterial hypertension, routine ultrasound imaging is not part of the initial work‑up; standard baseline investigations include fasting glucose (and HbA1c if elevated), lipid profile, serum sodium and potassium, creatinine with estimated GFR, urine albumin‑creatinine ratio, thyroid‑stimulating hormone, and a 12‑lead electrocardiogram to detect left‑ventricular hypertrophy, arrhythmias, or ischemic changes. 49

Indications for Specific Ultrasound Modalities

Echocardiography

• Transthoracic echocardiography is indicated when an abnormal ECG (e.g., signs of left‑ventricular hypertrophy), cardiac murmurs, or cardiac symptoms such as dyspnoea, chest pain, or reduced exercise capacity are present, to evaluate cardiac structure and function. 49
• When local resources permit, performing an echocardiogram in all newly diagnosed hypertensive patients can uncover subclinical left‑ventricular dysfunction and improve long‑term risk stratification, as echocardiographic findings have been shown to predict cardiovascular events over a 5‑year horizon. 49

Renal Ultrasound with Doppler

• A renal Doppler ultrasound should be obtained in patients with moderate to severe chronic kidney disease to assess renal parenchymal architecture and exclude obstructive lesions. 49
• In cases where renovascular hypertension is suspected—characterised by sudden onset or rapid worsening of hypertension, flash pulmonary oedema, a ≥50 % rise in serum creatinine within one week after initiating an ACE‑inhibitor or ARB, or audible abdominal bruits—renal Doppler imaging is recommended to evaluate renal artery stenosis. 49
• When renal parenchymal disease is suspected (e.g., history of recurrent urinary‑tract infections, obstructive symptoms, haematuria, palpable enlarged kidneys, or impaired renal function), renal ultrasound assists in identifying structural abnormalities. 49

Carotid and Femoral Ultrasound

• Carotid and femoral duplex ultrasound may be performed optionally to detect atherosclerotic plaques and assess arterial stiffness as part of cardiovascular risk stratification in hypertensive patients who already have documented vascular disease; these studies are not routine for all hypertensive individuals. 49

Summary of Ultrasound Recommendations

The decision to order any ultrasound study in the context of arterial hypertension should be driven by specific clinical clues rather than by routine imaging protocols. 49